EADV: Long-term apremilast results show what to expect for psoriasis
October 26, 2015|Rheumatology News
Author and Disclosure Information
AT THE EADV CONGRESS
“I would call the LIBERATE results a validation of the earlier data showing a very clean safety profile with this drug,” Dr. Reich said.
This is reflected in the product labeling, which unlike other systemic therapies for psoriasis includes no requirements for laboratory monitoring or tuberculosis testing.
Both the LIBERATE and the ESTEEM trials were sponsored by Celgene. Dr. Reich received research grants as an investigator in both programs.
